ARQT Stock Performance, Insider Transaction and News

ARQT - Arcutis Biotherapeutics, Inc.

Market Cap	629.58M	P/E	-	EPS this Y	59.00%	Ern Qtrly Grth	-
Income	-198.76M	Forward P/E	-2.76	EPS next Y	25.80%	50D Avg Chg	8.00%
Sales	132.06M	PEG	-0.60	EPS past 5Y	-	200D Avg Chg	-25.00%
Dividend	N/A	Price/Book	4.50	EPS next 5Y	9.80%	52W High Chg	-63.00%
Recommedations	1.90	Quick Ratio	7.90	Shares Outstanding	116.89M	52W Low Chg	41.00%
Insider Own	2.19%	ROA	-29.36%	Shares Float	85.87M	Beta	1.18
Inst Own	110.43%	ROE	-148.92%	Shares Shorted/Prior	24.86M/23.80M	Price	10.25
Gross Margin	92.32%	Profit Margin	-150.51%	Avg. Volume	1,262,433	Target Price	18.57
Oper. Margin	-162.28%	Earnings Date	Nov 1	Volume	568,776	Change	-3.03%

Healthcare | Biotechnology | United States

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc. News

11/20/24	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
11/20/24	Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors
11/19/24	Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
11/19/24	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
11/13/24	Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
11/11/24	Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
11/08/24	Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
11/07/24	Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...
11/06/24	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates
11/06/24	Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
11/06/24	High Growth Tech Stocks In The United States To Watch
11/04/24	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/28/24	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10/25/24	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
10/24/24	Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
10/23/24	Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
09:43 AM	Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis
06:00 AM	Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
10/18/24	Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
10/12/24	Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

ARQT Chatroom

johnnyutah007 Posted - 2 hours ago

$ARQT 👀

Finsh1st Posted - 3 hours ago

$ARQT Only 500k volume... must be a day trade.

Finsh1st Posted - 3 hours ago

$ARQT woh!

Finsh1st Posted - 9 hours ago

$ARQT AQST is the same. must be my broker... darn I'm tired was thinking something big was happening.

Finsh1st Posted - 9 hours ago

$ARQT Whats up? halted? no premarket nfo

SeraphineFrost Posted - 1 day ago

$ARQT $SEPN LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

RoyMunson69 Posted - 1 day ago

$ARQT The volatility is just wild for a commercial bio with a decent product

Franciscomaligno Posted - 1 day ago

$ARQT have u seen huge volume in ah ??? 367k !!! Today fireworks , glta !!!

Shlobby Posted - 1 day ago

$ARQT has some work still but riding that 50w to perfection

Dilly_Poppins Posted - 2 days ago

$ARQT seasonally this has done well December/January/February - banking on same. As per earnings call, no need to raise capital in market and good consistent growth. Break even by 2026. Mizuho expects a multi bagger over next handful of years

CrispDry Posted - 2 days ago

$ARQT currently a top 3 position for me. Feel quite secure here

zawojak Posted - 3 days ago

$ARQT It should come back to $10 level just before n2xt earnings... next year

zawojak Posted - 3 days ago

$ARQT The stock did pull back significantly last week as biotech had its worst week since 2020.

Franciscomaligno Posted - 3 days ago

$ARQT This sob don't respect anything , Expert fo MONEY !!! BURN IN HELL !!!

Affectionate_Jelly Posted - 5 days ago

$ARQT $BTBT Loading zone...

Rhody27 Posted - 6 days ago

$ARQT XBI getting hammered today as a result of the RFK nomination. This is getting pulled down with it.

Franciscomaligno Posted - 6 days ago

$ARQT Unfortunately this Is "normal" , i had PRVB for almost two years and It was always highly shorted , but One day... I gained almost $200k. For this one Will be the same , maybe Better . What Isn't normal ??? Stupid likes u posting here !!!

BugHunti Posted - 6 days ago

$ARQT nice! come to $8! will buy at 7.50$ and trash near 11$ or $10.50

Rhody27 Posted - 6 days ago

$ARQT adding

85Thebrit Posted - 6 days ago

$ARQT still making money on this, up and down..simple..it's criminal, 35K since last October..just ride the waves..nice supplement to the salary.

barecheeks Posted - 6 days ago

$ARQT you all gas this !?!? Pos stock. Pos company. Yall don’t know nothin about making money. Enjoy getting tossed and thrown around by shorts

Franciscomaligno Posted - 6 days ago

$ARQT i'll tell u a story , in 2022 PRVB started a distribution agreement for Teplizumab with Sanofi , next year One day of July PRVB jumped of 376% = bought by Sanofi. Now , Astrazeneca Just started a distribution agreement with ARQT for Roflumilast , if 2+2 makes 4 , something Is boiling here !!!

Finsh1st Posted - 6 days ago

$ARQT Missery loves company

Dilly_Poppins Posted - 6 days ago

$ARQT I put some ZORYVE 0.3 cream on my screen @ the 200dma, should go up now

Franciscomaligno Posted - 6 days ago

$ARQT same shit again and again !!! All penny market biotech are highly manipolated , and SEC IS SLEEPING , RIDICOULOUS !!!

barecheeks Posted - 6 days ago

$ARQT your stocks amazing guys

liadanielle Posted - 6 days ago

$ARQT Keep dropping YEAH!!! I’ll add when it bottoms out. Looking for my high and low sweet spots. Love this stock. In at 9 out at 11 every day!!

Carl83 Posted - 6 days ago

$ARQT Holding

JOEYD05 Posted - 6 days ago

$ARQT https://www.marketbeat.com/instant-alerts/gsa-capital-partners-llp-purchases-208599-shares-of-arcutis-biotherapeutics-inc-nasdaqarqt-2024-11-12/

zawojak Posted - 6 days ago

$ARQT Dead money until next quarter?

Analyst Ratings

Jefferies	Buy	Aug 28, 24
Needham	Buy	Aug 15, 24
Needham	Buy	Jul 30, 24
Needham	Buy	Jul 10, 24
Needham	Buy	May 15, 24
Mizuho	Buy	May 15, 24
Needham	Buy	Apr 12, 24
Goldman Sachs	Neutral	Feb 28, 24
Mizuho	Buy	Feb 28, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Burnett Patrick	See Remarks See Remarks	Jan 02	Sell	3.5408	1,325	4,692	57,032	01/03/24
Watanabe Todd Franklin	See Remarks See Remarks	May 31	Buy	6.38	1,463	9,334	515,145	12/01/23
Watanabe Todd Franklin	See Remarks See Remarks	May 31	Option	1.68	59,525	100,002	513,682	12/01/23
Matsuda Masaru	See Remark See Remark	Nov 18	Sell	1.98	1,850	3,663	46,634	11/21/23
Burnett Patrick	See Remarks See Remarks	Aug 18	Sell	7.05	1,605	11,315	58,357	08/22/23
Matsuda Masaru	See Remark See Remark	May 27	Sell	7.8	1,830	14,274	42,146	06/02/23
Welgus Howard G.	Director Director	Apr 17	Sell	13.97	8,500	118,745	165,825	04/18/23
Welgus Howard G.	Director Director	Apr 17	Option	1.68	8,500	14,280	174,325	04/18/23
Moore Matthew Richard	See Remarks See Remarks	Mar 02	Sell	16.17	1,610	26,034	11,690	03/06/23
Matsuda Masaru	See Remarks See Remarks	Mar 02	Sell	16.17	1,434	23,188	18,101	03/06/23
Burnett Patrick	See Remarks See Remarks	Mar 02	Sell	16.17	1,751	28,314	39,813	03/06/23
Watanabe Todd Franklin	See Remarks See Remarks	Feb 28	Sell	16.17	7,815	126,369	369,092	03/02/23
Burrows Scott L	Chief Financial Offi.. Chief Financial Officer	Feb 28	Sell	16.17	1,850	29,915	38,406	03/02/23
Lock Kenneth A.	Chief Commercial Off.. Chief Commercial Officer	Feb 28	Sell	16.17	2,368	38,291	43,260	03/02/23
OSBORNE DAVID W	Chief Technical Offi.. Chief Technical Officer	Feb 28	Sell	16.17	2,005	32,421	254,644	03/02/23
Welgus Howard G.	Director Director	Feb 15	Sell	16.98	8,500	144,330	165,825	02/21/23
Welgus Howard G.	Director Director	Feb 15	Option	1.68	8,500	14,280	174,325	02/21/23
Watanabe Todd Franklin	See Remarks See Remarks	Feb 13	Sell	17.02	1,000	17,020	376,907	02/15/23
Welgus Howard G.	Director Director	Jan 17	Sell	13.72	8,500	116,620	165,825	01/18/23
Welgus Howard G.	Director Director	Jan 17	Option	1.68	8,500	14,280	174,325	01/18/23
Burrows Scott L	Chief Financial Offi.. Chief Financial Officer	Sep 16	Option	1.6806	5,000	8,403	40,256	09/20/22
Watanabe Todd Franklin	President and CEO President and CEO	Sep 07	Sell	21.51	1,000	21,510	381,907	09/09/22
Welgus Howard G.	Director Director	Aug 15	Sell	24.7981	6,000	148,789	174,208	08/17/22
Watanabe Todd Franklin	President and CEO President and CEO	Aug 05	Option	1.68	2,500	4,200	654,371	08/09/22
Watanabe Todd Franklin	President and CEO President and CEO	Aug 05	Sell	24.74	2,500	61,850	651,871	08/09/22
Frazier Life Sciences VIII, L....	10% Owner 10% Owner	Aug 05	Buy	20.00	250,000	5,000,000	8,684,232	08/09/22
Turney Patricia A.	SVP, Operations SVP, Operations	Mar 23	Option	6.52	15,331	99,958	46,444	08/04/22
Welgus Howard G.	Director Director	Jul 18	Sell	24.3956	6,000	146,374	180,208	07/18/22
OSBORNE DAVID W	Chief Technical Offi.. Chief Technical Officer	Jul 08	Sell	25.4144	2,197	55,835	256,649	07/12/22
Watanabe Todd Franklin	President and CEO President and CEO	Jul 08	Option	1.68	7,087	11,906	658,958	07/12/22
Watanabe Todd Franklin	President and CEO President and CEO	Jul 08	Sell	25.28	13,500	341,280	651,871	07/12/22
Watanabe Todd Franklin	President and CEO President and CEO	Jul 06	Sell	22.07	1,000	22,070	658,284	07/07/22
Watanabe Todd Franklin	President and CEO President and CEO	May 05	Sell	21.76	1,000	21,760	658,667	05/05/22
Welgus Howard G.	Director Director	May 02	Option	1.13	2,500	2,825	184,396	05/03/22
Welgus Howard G.	Director Director	May 02	Sell	20.44	2,500	51,100	181,896	05/03/22
OSBORNE DAVID W	Chief Technical Offi.. Chief Technical Officer	Apr 21	Sell	20.4243	2,197	44,872	257,229	04/21/22
ORBIMED ADVISORS LLC	10% Owner 10% Owner	Apr 06	Sell	20.69	878,200	18,169,958	451,086	04/08/22
Watanabe Todd Franklin	President and CEO President and CEO	Apr 05	Sell	21.43	1,000	21,430	659,667	04/05/22
Welgus Howard G.	Director Director	Apr 01	Option	0.58	7,500	4,350	189,396	04/01/22
Welgus Howard G.	Director Director	Apr 01	Sell	20.02	7,500	150,150	181,896	04/01/22
Watanabe Todd Franklin	President and CEO President and CEO	Mar 09	Sell	17.00	300	5,100	660,667	03/11/22
Watanabe Todd Franklin	President and CEO President and CEO	Mar 03	Option	1.68	700	1,176	661,667	03/07/22
Watanabe Todd Franklin	President and CEO President and CEO	Mar 03	Sell	16.8	3,259	54,751	660,967	03/07/22
Burnett Patrick	See Remarks See Remarks	Mar 03	Sell	16.65	1,011	16,833	43,039	03/07/22
Lock Kenneth A.	Chief Commercial Off.. Chief Commercial Officer	Mar 03	Sell	16.65	1,023	17,033	44,011	03/07/22
Burrows Scott L	Chief Financial Offi.. Chief Financial Officer	Mar 03	Sell	16.65	303	5,045	35,256	03/07/22
Turney Patricia A.	SVP, Operations SVP, Operations	Mar 03	Sell	16.65	1,023	17,033	31,113	03/07/22
OSBORNE DAVID W	Chief Technical Offi.. Chief Technical Officer	Mar 03	Sell	16.65	856	14,252	259,426	03/07/22
Watanabe Todd Franklin	President and CEO President and CEO	Feb 09	Option	1.68	1,000	1,680	595,779	02/11/22
Watanabe Todd Franklin	President and CEO President and CEO	Feb 09	Sell	17	1,000	17,000	594,779	02/11/22